ArticleInternational journal of hematology2026
Daratumumab-based therapy in systemic AL amyloidosis including advanced cardiac involvement: a single center study.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the real-world effectiveness, overall survival (OS), durability of response, and tolerability of daratumumab-based therapy for systemic amyloid light-chain (AL) amyloidosis in Japan, where bortezomib and daratumumab were only recently introduced, using 3-year follow-up data.
methodsWe retrospectively reviewed 43 patients diagnosed with AL amyloidosis. Fifteen patients received daratumumab-containing regimens (Dara group) and 28 received non-daratumumab therapy (non-Dara group). Clinical characteristics, hematologic response (HR), organ response (OR), OS, and treatment tolerability were compared. Four patients with Mayo 2012 stage IV disease underwent stepwise dose modification of daratumumab-based therapy.
resultsThe Dara group showed significantly higher HR (93% vs. 35.7%) and OR (71.4% vs. 19.2%) and improved OS compared with the non-Dara group. At a median follow-up of 34 months, 11 of the 12 surviving patients in the Dara group maintained a complete HR. In Mayo stage IV cases, reduced-intensity induction with daratumumab and dexamethasone, followed by gradual intensification, achieved an OR in most patients evaluated.
conclusionsDaratumumab-based therapy resulted in high response rates, durable remission, and improved OS in patients with systemic AL amyloidosis. Daratumumab-based strategies may benefit patients across risk groups, including those with advanced cardiac involvement.
Indexed as
Identifiers
42149416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.